Cardiol Therapeutics (CRDL) EBITDA (2020 - 2026)

Cardiol Therapeutics has reported EBITDA for 7 years, with the latest figure at $7.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 236.59% year-over-year to $7.9 million; the trailing twelve-month figure through Mar 2026 stood at $902233.4 (up 125.96% YoY), and the FY2025 full-year result was -$24.6 million, up 14.65% from the prior year.
• EBITDA for Q1 2026 stood at $7.9 million, up from -$7.2 million in the prior quarter.
• The five-year high for EBITDA was $7.9 million in Q1 2026, with the low at -$9.3 million in Q3 2024.
• Historically, EBITDA has averaged -$10562.6 across 5 years, with a median of $197674.4 in 2024.
• Annual changes were most pronounced in 2025 — EBITDA sank 184.78% — and 2026, when it jumped 236.59%.
• Cardiol Therapeutics' EBITDA stood at -$6.7 million in 2022, then surged by 33.98% to -$4.4 million in 2023, then tumbled by 110.93% to -$9.3 million in 2024, then advanced by 22.4% to -$7.2 million in 2025, then soared by 208.96% to $7.9 million in 2026.
• The last three EBITDA figures came in at $7.9 million (Q1 2026), -$7.2 million (Q3 2025), and $6.0 million (Q2 2025), per Business Quant data.